JP2019507130A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019507130A5 JP2019507130A5 JP2018539873A JP2018539873A JP2019507130A5 JP 2019507130 A5 JP2019507130 A5 JP 2019507130A5 JP 2018539873 A JP2018539873 A JP 2018539873A JP 2018539873 A JP2018539873 A JP 2018539873A JP 2019507130 A5 JP2019507130 A5 JP 2019507130A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- heterocycloalkyl
- compound according
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 86
- 150000001875 compounds Chemical class 0.000 claims description 60
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 53
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 43
- 125000001072 heteroaryl group Chemical group 0.000 claims description 30
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 26
- 125000003118 aryl group Chemical group 0.000 claims description 26
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 24
- 125000003342 alkenyl group Chemical group 0.000 claims description 19
- 125000001188 haloalkyl group Chemical group 0.000 claims description 17
- 125000000304 alkynyl group Chemical group 0.000 claims description 15
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 14
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 125000004429 atom Chemical group 0.000 claims description 12
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 11
- 230000002159 abnormal effect Effects 0.000 claims description 10
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 10
- 230000004154 complement system Effects 0.000 claims description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 9
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 6
- 125000004414 alkyl thio group Chemical group 0.000 claims description 4
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 4
- 125000003107 substituted aryl group Chemical group 0.000 claims description 4
- 125000002837 carbocyclic group Chemical group 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 2
- 208000035913 Atypical hemolytic uremic syndrome Diseases 0.000 claims description 2
- 101100240520 Caenorhabditis elegans nhr-14 gene Proteins 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 208000011038 Cold agglutinin disease Diseases 0.000 claims description 2
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 claims description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 2
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 claims description 2
- 208000012902 Nervous system disease Diseases 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 claims description 2
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims description 2
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000003282 alkyl amino group Chemical group 0.000 claims description 2
- 125000000732 arylene group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 208000015114 central nervous system disease Diseases 0.000 claims description 2
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 2
- 208000022401 dense deposit disease Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 2
- 125000005549 heteroarylene group Chemical group 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 208000026278 immune system disease Diseases 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 230000000626 neurodegenerative effect Effects 0.000 claims description 2
- 208000008795 neuromyelitis optica Diseases 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims description 2
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 201000008171 proliferative glomerulonephritis Diseases 0.000 claims description 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 4
- 0 CCCCC*(C(C(C)C(N1C)=O)C1=O)=C Chemical compound CCCCC*(C(C(C)C(N1C)=O)C1=O)=C 0.000 description 6
- XDTMQSROBMDMFD-UHFFFAOYSA-N C1CCCCC1 Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- -1 haloalkyl compound Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021126415A JP7257462B2 (ja) | 2016-02-01 | 2021-08-02 | ベンゾピラゾール化合物及びその類似体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662289653P | 2016-02-01 | 2016-02-01 | |
| US62/289,653 | 2016-02-01 | ||
| PCT/US2017/015953 WO2017136395A1 (en) | 2016-02-01 | 2017-02-01 | Benzopyrazole compounds and analogues thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021126415A Division JP7257462B2 (ja) | 2016-02-01 | 2021-08-02 | ベンゾピラゾール化合物及びその類似体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019507130A JP2019507130A (ja) | 2019-03-14 |
| JP2019507130A5 true JP2019507130A5 (cg-RX-API-DMAC7.html) | 2020-02-27 |
| JP6924766B2 JP6924766B2 (ja) | 2021-08-25 |
Family
ID=59500923
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018539873A Active JP6924766B2 (ja) | 2016-02-01 | 2017-02-01 | ベンゾピラゾール化合物及びその類似体 |
| JP2021126415A Active JP7257462B2 (ja) | 2016-02-01 | 2021-08-02 | ベンゾピラゾール化合物及びその類似体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021126415A Active JP7257462B2 (ja) | 2016-02-01 | 2021-08-02 | ベンゾピラゾール化合物及びその類似体 |
Country Status (30)
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3340983B1 (en) | 2015-08-26 | 2023-10-04 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| AR105809A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos médicos |
| WO2017035357A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Phosphonate compounds for treatment of medical disorders |
| ES2908479T3 (es) | 2015-08-26 | 2022-04-29 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| WO2017035361A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Disubstituted compounds for the treatment of medical disorders |
| TWI854164B (zh) | 2016-02-01 | 2024-09-01 | 美商百歐克斯製藥公司 | 苯并吡唑化合物及其類似物 |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| MX2019010381A (es) | 2017-03-01 | 2020-01-21 | Achillion Pharmaceuticals Inc | Compuestos farmaceuticos de arilo, heteroarilo y heterociclicos para el tratamiento de trastornos medicos. |
| EP3589287B1 (en) | 2017-03-01 | 2022-09-14 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for treatment of medical disorders |
| TW202535858A (zh) * | 2018-04-06 | 2025-09-16 | 美商百歐克斯製藥公司 | 取代的苯并呋喃、苯并吡咯、苯并噻吩及結構相關的補體抑制劑 |
| CN112839648B (zh) | 2018-06-07 | 2025-04-04 | 达萨玛治疗公司 | Sarm1抑制剂 |
| JP7538113B2 (ja) | 2018-08-20 | 2024-08-21 | アキリオン ファーマシューティカルズ，インコーポレーテッド | 補体ｄ因子の医学的障害の治療のための医薬化合物 |
| MX2021002640A (es) | 2018-09-06 | 2021-07-16 | Achillion Pharmaceuticals Inc | Formas morficas de los inhibidores del factor d del complemento. |
| US11814391B2 (en) | 2018-09-06 | 2023-11-14 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
| MX2021003425A (es) | 2018-09-25 | 2021-07-16 | Achillion Pharmaceuticals Inc | Formas morficas de los inhibidores del factor d del complemento. |
| AU2019406830A1 (en) | 2018-12-17 | 2021-07-08 | Achillion Pharmaceuticals, Inc. | Targeted dosing for the treatment of complement mediated disorders |
| US12083114B2 (en) | 2018-12-19 | 2024-09-10 | Disarm Therapeutics, Inc. | Inhibitors of SARM1 in combination with neuro-protective agents |
| WO2020198062A1 (en) | 2019-03-22 | 2020-10-01 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement mediated disorders |
| UY38909A (es) * | 2019-10-09 | 2021-05-31 | Biocryst Pharm Inc | Inhibidores del factor d del complemento para administración oral |
| UY38912A (es) * | 2019-10-09 | 2021-05-31 | Biocryst Pharm Inc | Inhibidores del factor d del complemento para administración oral |
| US20250197403A1 (en) | 2020-02-20 | 2025-06-19 | Achillion Pharmaceuticals, Inc. | Heteroaryl compounds for treatment of complement factor d mediated disorders |
| AR121715A1 (es) | 2020-04-03 | 2022-06-29 | Biocryst Pharm Inc | Pirrolopirimidinaminas como inhibidores del sistema del complemento |
| CN113512025B (zh) * | 2020-07-31 | 2023-01-06 | 四川大学 | 一种吲唑酯类化合物及其制药用途 |
| US20250129371A1 (en) | 2023-10-11 | 2025-04-24 | Regeneron Pharmaceuticals, Inc. | Treatment Of Macular Degeneration With Complement Factor D (CFD) Inhibitors |
| CN119638611B (zh) * | 2024-12-08 | 2025-10-31 | 胥江生物科技(苏州)有限公司 | N-乙酰-5-羟色胺衍生物、免疫原、抗体及检测试剂制备与应用 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| LU86084A1 (fr) | 1985-09-20 | 1987-04-02 | Faco Sa | Apparei de massage electrique |
| US5102417A (en) | 1985-11-07 | 1992-04-07 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
| US4800882A (en) | 1987-03-13 | 1989-01-31 | Cook Incorporated | Endovascular stent and delivery system |
| US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| US4886062A (en) | 1987-10-19 | 1989-12-12 | Medtronic, Inc. | Intravascular radially expandable stent and method of implant |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| WO1990013332A1 (en) | 1989-05-11 | 1990-11-15 | Cedars-Sinai Medical Center | Stent with sustained drug delivery |
| EP0470246B1 (en) | 1990-02-28 | 1995-06-28 | Medtronic, Inc. | Intralumenal drug eluting prosthesis |
| US5429634A (en) | 1993-09-09 | 1995-07-04 | Pdt Systems | Biogenic implant for drug delivery and method |
| US5419760A (en) | 1993-01-08 | 1995-05-30 | Pdt Systems, Inc. | Medicament dispensing stent for prevention of restenosis of a blood vessel |
| CN1141627A (zh) | 1994-02-22 | 1997-01-29 | 默里尔药物公司 | 用于治疗雌激素相关肿瘤和疾病的新吲哚衍生物 |
| US6774278B1 (en) | 1995-06-07 | 2004-08-10 | Cook Incorporated | Coated implantable medical device |
| WO1998009957A1 (en) | 1996-09-04 | 1998-03-12 | Warner-Lambert Company | Compounds for and a method of inhibiting matrix metalloproteinases |
| EP0927159A1 (en) | 1996-09-10 | 1999-07-07 | Medinox, Inc. | Polydithiocarbamate-containing macromolecules and the use thereof for therapeutic and diagnostic applications |
| US6596770B2 (en) | 2000-05-05 | 2003-07-22 | Medinox, Inc. | Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor |
| US6660845B1 (en) * | 1999-11-23 | 2003-12-09 | Epoch Biosciences, Inc. | Non-aggregating, non-quenching oligomers comprising nucleotide analogues; methods of synthesis and use thereof |
| DE60303441T2 (de) * | 2002-02-08 | 2006-09-21 | Merck & Co., Inc. | N-biphenylmethylaminocycloalkancarboxamid-derivative |
| US6770729B2 (en) | 2002-09-30 | 2004-08-03 | Medtronic Minimed, Inc. | Polymer compositions containing bioactive agents and methods for their use |
| EP1433778A1 (en) * | 2002-12-23 | 2004-06-30 | Jerini AG | Use of nitriles as rotamase inhibitors |
| US7335644B2 (en) * | 2003-03-31 | 2008-02-26 | Council Of Scientific And Industrial Research | Anti-hypertensive molecules and process for preparation thereof |
| JP2007008914A (ja) * | 2004-10-27 | 2007-01-18 | Nissan Chem Ind Ltd | 置換ジアミン化合物および農園芸用殺菌剤 |
| US7807704B2 (en) * | 2006-03-30 | 2010-10-05 | Chemocentryx, Inc. | Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 |
| WO2009106980A2 (en) * | 2008-02-29 | 2009-09-03 | Pfizer Inc. | Indazole derivatives |
| MX2011003991A (es) * | 2008-10-17 | 2011-06-24 | Exelixis Inc | Antagonistas del receptor esfingosina-1-fosfato. |
| US8518945B2 (en) | 2010-03-22 | 2013-08-27 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
| CN102464654B (zh) * | 2010-11-12 | 2016-01-13 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| WO2012093101A1 (en) | 2011-01-04 | 2012-07-12 | Novartis Ag | Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd) |
| US10093674B2 (en) * | 2011-05-31 | 2018-10-09 | Brandeis University | Supramolecular nanofibers and hydrogels based on nucleic acids functionalized with nucleobases |
| WO2012166706A2 (en) * | 2011-05-31 | 2012-12-06 | Brandeis University | Supramolecular nanofibers and hydrogels based on oligopeptides functionalized with nucleobases |
| ES2464598T3 (es) | 2011-07-22 | 2014-06-03 | Université Joseph Fourier | Nuevos derivados bis-indólicos, procedimiento para su preparación, y sus utilizaciones como fármaco |
| ME03332B (me) | 2011-09-14 | 2019-10-20 | Samumed Llc | Indazol-3-karboksamidi i njihova upotreba kao inhibitora signalnog puta wnt/b-katenina |
| US9187474B2 (en) * | 2012-03-07 | 2015-11-17 | Deciphera Pharmaceuticals, Llc | Raf inhibitor compounds |
| EA027113B1 (ru) | 2012-05-04 | 2017-06-30 | Новартис Аг | Регуляторы пути комплемента и их применение |
| ES2712190T3 (es) | 2012-06-28 | 2019-05-09 | Novartis Ag | Moduladores de la vía del complemento y sus usos |
| WO2014002051A2 (en) | 2012-06-28 | 2014-01-03 | Novartis Ag | Complement pathway modulators and uses thereof |
| US9388199B2 (en) | 2012-06-28 | 2016-07-12 | Novartis Ag | Pyrrolidine derivatives and their use as complement pathway modulators |
| EA201590200A1 (ru) | 2012-07-12 | 2015-08-31 | Новартис Аг | Модуляторы пути активации комплемента и их применение |
| PT2872157T (pt) * | 2012-07-12 | 2020-04-30 | Hangzhou Dac Biotech Co Ltd | Conjugados de moléculas de ligação celular com agentes citotóxicos |
| EP2900642B1 (en) | 2012-09-27 | 2018-02-28 | F. Hoffmann-La Roche AG | Substituted sulfonamide compounds |
| CN112047927A (zh) * | 2013-03-15 | 2020-12-08 | 德西费拉制药有限责任公司 | 展现抗癌和抗增殖活性的n-酰基-n′-(吡啶-2-基)脲及类似物 |
| ES2950424T3 (es) * | 2013-07-03 | 2023-10-09 | Takeda Pharmaceuticals Co | Compuesto de amida |
| AP2016009435A0 (en) * | 2014-02-25 | 2016-09-30 | Achillion Pharmaceuticals Inc | Ether compounds for treatment of complement mediated disorders |
| US11241394B2 (en) | 2015-06-19 | 2022-02-08 | The Regents Of The University Of California | Treating vasculature related diseases or disorders using nanoparticles |
| WO2017035415A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Alkyne compounds for treatment of immune and inflammatory disorders |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| WO2017035411A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Ether compounds for treatment of immune and inflammatory disorders |
| ES2908479T3 (es) | 2015-08-26 | 2022-04-29 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios |
| EP3340983B1 (en) | 2015-08-26 | 2023-10-04 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| WO2017035418A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Disubstituted compounds for treatment of immune and inflammatory disorders |
| WO2017035413A2 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Carbamate, ester, and ketone compounds for treatment of immune and inflammatory disorders |
| TWI854164B (zh) | 2016-02-01 | 2024-09-01 | 美商百歐克斯製藥公司 | 苯并吡唑化合物及其類似物 |
-
2017
- 2017-01-26 TW TW110141309A patent/TWI854164B/zh active
- 2017-01-26 TW TW106103180A patent/TWI747873B/zh active
- 2017-01-30 AR ARP170100240A patent/AR107488A1/es unknown
- 2017-02-01 RS RS20210979A patent/RS62187B2/sr unknown
- 2017-02-01 WO PCT/US2017/015953 patent/WO2017136395A1/en not_active Ceased
- 2017-02-01 ES ES17748044T patent/ES2882495T7/es active Active
- 2017-02-01 DK DK17748044.9T patent/DK3411411T6/da active
- 2017-02-01 AU AU2017213768A patent/AU2017213768B2/en active Active
- 2017-02-01 IL IL290154A patent/IL290154B2/en unknown
- 2017-02-01 MY MYPI2018001324A patent/MY201629A/en unknown
- 2017-02-01 MA MA43979A patent/MA43979B1/fr unknown
- 2017-02-01 JP JP2018539873A patent/JP6924766B2/ja active Active
- 2017-02-01 PL PL17748044T patent/PL3411411T6/pl unknown
- 2017-02-01 EP EP21173901.6A patent/EP3925956B1/en active Active
- 2017-02-01 SM SM20210494T patent/SMT202100494T1/it unknown
- 2017-02-01 CA CA3011549A patent/CA3011549A1/en active Pending
- 2017-02-01 SG SG11201805940QA patent/SG11201805940QA/en unknown
- 2017-02-01 SI SI201730796T patent/SI3411411T1/sl unknown
- 2017-02-01 LT LTEP17748044.9T patent/LT3411411T/lt unknown
- 2017-02-01 CN CN202210705604.0A patent/CN115490751A/zh active Pending
- 2017-02-01 ES ES21173901T patent/ES2982426T3/es active Active
- 2017-02-01 EA EA201891703A patent/EA039719B1/ru unknown
- 2017-02-01 SG SG10202108797UA patent/SG10202108797UA/en unknown
- 2017-02-01 CN CN201780021413.XA patent/CN109121414B/zh active Active
- 2017-02-01 MX MX2018008869A patent/MX2018008869A/es unknown
- 2017-02-01 EP EP17748044.9A patent/EP3411411B3/en active Active
- 2017-02-01 HR HRP20210926TT patent/HRP20210926T4/hr unknown
- 2017-02-01 HU HUE17748044A patent/HUE055258T2/hu unknown
- 2017-02-01 US US16/073,934 patent/US10849883B2/en active Active
- 2017-02-01 PH PH1/2018/501537A patent/PH12018501537B1/en unknown
- 2017-02-01 KR KR1020187024635A patent/KR102828456B1/ko active Active
- 2017-02-01 MD MDE20181197T patent/MD3411411T2/ro unknown
- 2017-02-01 PT PT177480449T patent/PT3411411T/pt unknown
-
2018
- 2018-07-11 IL IL260545A patent/IL260545B/en unknown
- 2018-07-19 MX MX2022007915A patent/MX2022007915A/es unknown
- 2018-08-27 CO CONC2018/0008916A patent/CO2018008916A2/es unknown
-
2020
- 2020-08-26 US US17/003,552 patent/US11559515B2/en active Active
-
2021
- 2021-08-02 JP JP2021126415A patent/JP7257462B2/ja active Active
- 2021-08-03 CY CY20211100696T patent/CY1124652T1/el unknown
-
2023
- 2023-01-23 US US18/158,029 patent/US12485109B2/en active Active